• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday

    7/20/23 10:02:28 AM ET
    $HCCI
    $JNJ
    $NBTX
    $OLO
    Miscellaneous
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCCI alert in real time by email

    U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session.

    • Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares rose 12.3% to $22.59.
    • Heritage-Crystal Clean, Inc (NASDAQ:HCCI) surged 9.6% to $45.96 after the company announced it will be acquired by J.F. Lehman & Company for $1.2 billion.
    • Zions Bancorporation, National Association (NASDAQ:ZION) gained 9.4% to $37.72 after the company reported second-quarter earnings results.
    • Olo Inc. (NYSE:OLO) shares jumped 9.4% to $7.35. Piper Sandler upgraded Olo from Neutral to Overweight and announced a $9 price target.
    • Select Medical Holdings Corporation (NYSE:SEM) rose 9.1% to $32.87.
    • Proterra Inc. (NASDAQ:PTRA) climbed 8.5% to $1.6609.
    • Nanobiotix S.A. (NASDAQ:NBTX) shares gained 8.4% to $7.77 as the company said first patient was injected in new Phase 1/2 study evaluating radiotherapy-activated NBTXR3 plus anti-PD-1 for patients with advanced cancers.
    • Savara Inc. (NASDAQ:SVRA) rose 7.7% to $3.49.
    • LendingTree, Inc. (NASDAQ:TREE) jumped 7.7% to $28.00. LendingTree named Scott Peyree as Chief Operating Officer and President of Marketplace Businesses.
    • Johnson & Johnson (NYSE:JNJ) gained 4.8% to $166.37 after the company posted upbeat second-quarter results and lifted annual outlook.

     

    Read More: Top 5 Energy Stocks That May Plunge In July

    Get the next $HCCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCCI
    $JNJ
    $NBTX
    $OLO

    CompanyDatePrice TargetRatingAnalyst
    Zions Bancorporation N.A.
    $ZION
    3/12/2026Neutral
    Brean Capital
    Zions Bancorporation N.A.
    $ZION
    3/9/2026$65.00Neutral → Outperform
    Robert W. Baird
    Select Medical Holdings Corporation
    $SEM
    3/3/2026$16.50Outperform → Sector Perform
    RBC Capital Mkts
    Zions Bancorporation N.A.
    $ZION
    3/2/2026$75.00Equal-Weight → Overweight
    Morgan Stanley
    Zions Bancorporation N.A.
    $ZION
    2/9/2026$65.00Outperform → Neutral
    Robert W. Baird
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Tarsus Pharmaceuticals Inc.
    $TARS
    12/9/2025$100.00Overweight
    Barclays
    More analyst ratings

    $HCCI
    $JNJ
    $NBTX
    $OLO
    SEC Filings

    View All

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    3/31/26 4:41:24 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Nanobiotix S.A.

    20-F - Nanobiotix S.A. (0001760854) (Filer)

    3/31/26 4:27:06 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    3/30/26 6:00:09 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brean Capital resumed coverage on Zions Bancorp

    Brean Capital resumed coverage of Zions Bancorp with a rating of Neutral

    3/12/26 3:51:49 PM ET
    $ZION
    Major Banks
    Finance

    Zions Bancorp upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Zions Bancorp from Neutral to Outperform and set a new price target of $65.00

    3/9/26 8:45:59 AM ET
    $ZION
    Major Banks
    Finance

    Select Medical downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Select Medical from Outperform to Sector Perform and set a new price target of $16.50

    3/3/26 8:21:50 AM ET
    $SEM
    Hospital/Nursing Management
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

    Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl

    3/31/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

    – A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –  IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evaluating TP-05 (lotilaner), a novel investigational oral therapy designed to potentially prevent Lyme disease by killing Lyme-infected ticks before disease transmission occurs. Calliope is a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the safety, tolerability and pharmacokinetics of orally administered TP-05 in approximately 700 healthy adults at r

    3/31/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

    -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with the U.S. Food and Drug Administration (FDA), with an Action Date of August 22, 2026 -- -- MOLBREEVI MAA Was Submitted to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) in March 2026 -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP; the submission will now be reviewed by the Committee for Medicinal Products for Human Use (CHMP)

    3/30/26 8:05:00 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Richards Robert Ryan

    4 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Issuer)

    4/2/26 4:34:28 PM ET
    $ZION
    Major Banks
    Finance

    SEC Form 4 filed by Miller Rena A.

    4 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Issuer)

    4/2/26 4:32:32 PM ET
    $ZION
    Major Banks
    Finance

    SEC Form 4 filed by Lee Vivian S

    4 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Issuer)

    4/1/26 7:54:17 PM ET
    $ZION
    Major Banks
    Finance

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Simmons Harris H bought $265,635 worth of shares (4,500 units at $59.03), increasing direct ownership by 0.34% to 1,317,493 units (SEC Form 4)

    4 - ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (0000109380) (Issuer)

    2/25/26 4:33:19 PM ET
    $ZION
    Major Banks
    Finance

    Director Hawkins Richard J bought $98,572 worth of shares (48,225 units at $2.04), increasing direct ownership by 72% to 115,466 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/23/25 2:39:22 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccracken Joseph S bought $20,825 worth of shares (10,000 units at $2.08), increasing direct ownership by 4% to 260,837 units (SEC Form 4)

    4 - Savara Inc (0001160308) (Issuer)

    6/2/25 7:59:29 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Savara Inc.

    SC 13G - Savara Inc (0001160308) (Subject)

    11/27/24 11:01:58 AM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Savara Inc.

    SC 13G/A - Savara Inc (0001160308) (Subject)

    11/14/24 5:48:34 PM ET
    $SVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

    Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl

    3/31/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of

    3/2/26 4:30:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCCI
    $JNJ
    $NBTX
    $OLO
    Leadership Updates

    Live Leadership Updates

    View All

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vectra Bank Colorado welcomes Dominic Karaba as its next President & CEO

    Vectra Bank Welcomes New Local Leadership DENVER, Nov. 10, 2025 /PRNewswire/ -- Vectra Bank Colorado is proud to announce the appointment of Dominic Karaba as its next President and CEO. Karaba succeeds Bruce Alexander, who will retire after a 25-year career at Vectra Bank. This transition marks an exciting chapter for Vectra Bank, as Vectra continues its commitment to local leadership, community engagement, and pro-active relationship banking. Karaba brings a wealth of experience to Vectra Bank, having served in senior executive roles in Commercial and Business banking in Col

    11/10/25 2:43:00 PM ET
    $ZION
    Major Banks
    Finance